Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Breast 2Thoracic 1Sarcoma 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Recurrence 1Hodgkin Disease 1

Interventions

Rituximab 377Cyclophosphamide 180Bendamustine Hydrochloride 110obinutuzumab 100Vincristine 95fludarabine 92Prednisone 90Doxorubicin 90ibrutinib 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24Prednisolone 23tositumomab I-131 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Clinical Trials, Phase I as Topic × Lymphoid × Clear all
NCT01572519 2020-11-20

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Janssen Research & Development, LLC

Phase 1 Completed
21 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡